HUMAHumacyte Inc. Common Stock

Phase III trial shows 91 more catheter-free days for dialysis patients.

Humacyte earnings update and stock context Humacyte (HUMA) reported second quarter 2026 results that included revenue of US$0.406 million and a net loss of US$36.8 million, alongside recent Nasdaq compliance pressure after its share price stayed below US$1.00. For the first half of 2026, the company reported revenue of US$0.901 million and a net loss of US$54.42 million. Earnings per share moved from a small profit a year ago to a basic loss of US$0.25 from continuing operations. Humacyte...

Humacyte stock has had a very rough run over the last several years, and current valuation checks now lean toward the shares looking expensive rather than like a clear bargain. Humacyte has declined 93.3% over the past 5 years, which puts recent pricing in the context of a very long and deep drawdown for existing shareholders. Recent progress in tissue engineered vessel programs and regulatory milestones may support expectations for future revenue, while the risk that clinical or regulatory...

Humacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients. The company plans to file a supplemental Biologics License Application based on the female cohort results from the dialysis access trial. The FDA accepted an Investigational New Drug application for Humacyte’s new coronary vessel candidate, allowing clinical development to proceed. This progress at Humacyte is part of a wider push...

Despite a slow commercial quarter, the company's positive Phase III dialysis data and upcoming sBLA submission position it for significant growth in 2027.

Moby summary of Humacyte, Inc.'s Q2 2026 earnings call

Humacyte (NASDAQ:HUMA) reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study. Commercial sales totaled

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -70.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from its prior day's close.

Amgen (AMGN) delivered earnings and revenue surprises of +12.32% and +6.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.63, signifying a -6.44% move from its prior day's close.

In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.67, marking a +2.22% move from the previous day.

Humacyte, Inc. (HUMA) closed at $0.66 in the latest trading session, marking a -1.28% move from the prior day.

Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.